EntreMed, Inc. (NASDAQ:ENMD)
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.
ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.
ENMD previously announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.
The trial was an open-label, single-arm, multi-center-study of ENMD-2076 dosed orally as a single agent in patients with platinum-resistant recurrent ovarian, peritoneal or tubal cancer. Sixty-four patients were enrolled of which 57 were evaluable at the time of the presentation. The primary endpoint for the study was progression-free survival rate at six months.
Secondary end-points include response rate, duration of response, and overall survival.
ENMD-2076 demonstrated clinical activity when administered daily orally as a single agent. Interim data from 57 evaluable patients showed a six-month progression free survival rate of 19%. Of the evaluable patients, four patients achieved a partial response and 30 patients achieved stable disease as measured by RECIST v1.1. Median overall survival has not yet been reached. The side effect profile was consistent with activity against ENMD-2076's targets, in particular, VEGFR2 and Aurora A. Studies to evaluate potential markers of ENMD-2076 in this patient group are ongoing.
The study was conducted at six sites in the United States and Canada and included Dana-Farber Cancer Institute, Indiana University Melvin & Bren Simon Cancer Center, University of Chicago Medical Center, Memorial Sloan-Kettering Cancer Center, University of Colorado Cancer Center, and Princess Margaret Hospital.
The data were presented by the principal investigator for the study, Dr. Ursula A. Matulonis, medical director of gynecologic oncology at Dana-Farber Cancer Institute and associate professor of medicine, Harvard Medical School, during a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2011 in Chicago, Illinois.
For more information about EntreMed, Inc. please visit http://www.entremed.com
Cleantech Transit, Inc. (CLNO.OB)
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector.
CLNO (”Cleantech”) previously reported 500 KW biomass gasification facility located in Merced, California has successfully passed its interconnection tests and is now connected to the utility distribution grid.
The gasification technology uses a non-combustion process to convert Ag and other woody residues into a hydrogen rich gas (”syngas”), which is then converted into electricity, along with heat and biochar (a useful byproduct that captures carbon in solid form and can be used as a soil amendment).
The Merced plant is expected to produce enough electricity to power about 400 homes. The plant connected to the electricity grid under California’s feed-in-tariff with a 15-year power purchase agreement.
In addition, Cleantech Transit Inc. recently provided additional details after achieving success on the 500 KW facility and successfully moving past the interconnection testing stage.
Coming on the recent success at the 500KW facility in Merced, California this poises Phoenix Energy to become a leading developer of renewable biomass distributed generation plants that utilize local resources for local energy.
Currently there are two additional projects being pre-certified by Phoenix Energy in California. The projects are each projected to be 1 MW biomass gasification facilities that will provide both electricity and process heat energy. Each facility will provide enough electricity to power approximately 800 homes as well as process heat to be used in drying agricultural products. The projects are expected to complete by the end of 2012.
Cleantech Transit, Inc. has expanded its focus to invest directly in specific green projects that can maximize shareholder value.
For more information about Cleantech Transit, Inc. please visit http://www.cleantechtransitinc.com
Power3 Medical Products, Inc. (PWRM.OB)
Power3 Medical Products, Inc. applies proprietary methodology to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro.
BC-SeraPro is a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials.
The global mammogram market is estimated at approximately $10 billion by the World Health Organization(WHO) and is growing especially in Asia where the incidences of breast cancer occur more frequently and at a younger age.
Also, NuroPro is a series of three separate and distinct blood serum tests designed to diagnose: Alzheimer’s, Parkinson’s or Lou Gehrig’s disease (ALS) in individuals.
The NuroPro Blood Test is PWRM’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease . Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
The U.S. blood market was worth $7.8 billion in 2007. It should reach $9.5 million by 2012, a compound annual growth rate (CAGR) of 5.7%. (Source: BBC Research)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com
Mettler-Toledo International, Inc. (NYSE:MTD) announced the webcast of its presentation at the Jefferies Global Healthcare Conference in New York on Wednesday, June 8, 2011, at 10:00 a.m. Eastern Time. To hear a live webcast of the presentation, visit the investor relations page on the Company's Web site at www.mt.com/investors. A replay of the webcast will be available for seven days.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. The company was founded in 1991 and is headquartered in Greifensee, Switzerland.
Precision Castparts Corp. (NYSE:PCP) has declared a quarterly cash dividend of $0.03 per share on the company's common stock payable on July 5, 2011, to shareholders of record at the close of business on June 10, 2011.
Precision Castparts Corp. (PCC) manufactures and sells metal components and products worldwide. The company was founded in 1949 and is based in Portland, Oregon.
Salesforce.com (NYSE:CRM) the enterprise cloud computing company, announced that Parker Harris, Executive Vice President, Technology, will present at the ISI Group hosted Bus Tour on Wednesday, June 8, 2011 at 10:00am (PT) / 1:00pm (ET) in San Francisco, CA.
salesforce.com, inc. provides customer and collaboration relationship management (CRM) services to various businesses and industries worldwide. It also offers a technology platform for customers and developers to build and run business applications.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (CLNO.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).